Sir, Since the introduction of the first antibiotic agents into the therapy of bacterial diseases, the development of resistance to antibiotics in human bacterial pathogens has been extensively described. For Legionella, an environmental pathogen with a facultative intracellular lifestyle and the causative agent of a form of atypical pneumonia, selection of in vitro mutants against erythromycin, ciprofloxacin, norfloxacin and rifampicin has been described. No isolates resistant in vivo were detected for a long time.
1,2 However, the first ciprofloxacin-resistant strain isolated from a clinical sample has been described recently. 3 Furthermore, the possibility of selection for fluoroquinolone resistance by antibiotic treatment of Legionella pneumophila has been reported. 4 Testing of L. pneumophila for antimicrobial susceptibility has not yet been standardized definitively because of the difficulty of growing bacteria on buffered yeast extract media containing charcoal, which is necessary for adequate growth of Legionella. This results in reduced activity of the most relevant antimicrobials and therefore leads to increasing MICs. 5 The use of control strains to ensure that growth conditions are adequate is essential for accurate evaluation of the results. Furthermore, the MIC values for the control strains should be within those for the WT population. 6 We performed antimicrobial susceptibility testing of a large set of clinical L. pneumophila isolates from Germany. The goal of this study was to collect data to survey the WT distribution of L. pneumophila in a defined geographical area.
A total of 100 strains of L. pneumophila serogroup 1, which were isolated from clinical specimens during the period 2001-16, were chosen for testing of their susceptibility to eight antimicrobial agents: levofloxacin, moxifloxacin, ciprofloxacin, rifampicin, azithromycin, clarithromycin, erythromycin and doxycycline. The isolates were community acquired (61%), nosocomially acquired (18%) or travel associated (15%). The source of 6% of isolates could not be identified. The strains were subtyped using Dresden Panel monoclonal antibodies (MAbs) and sequence-based typing (SBT) according to the European Study Group for Legionella Infections (ESGLI) SBT protocol. The MICs were determined after incubation of the isolates on buffered charcoal yeast extract agar supplemented with a-ketoglutarate (BCYE-a) for 48 h by using the Etest (bioMérieux, France). The results were interpreted using published epidemiological cut-off values (ECOFFs) and recently determined tentative EUCAST breakpoints for L. pneumophila. 5, 6 In each experiment, L. pneumophila strain ATCC 33152 was used as a control strain and its MICs were always below the highest MICs for WT populations. 5, 6 The MAb typing showed the prevalence of MAb subtypes Knoxville (30%) and Philadelphia (26%) in the strains investigated in this study. The analysed isolates belonged to 39 different STs with ST1 the most prominent (17%). All isolates showed MIC values lower than or equal to the ECOFFs. In contrast, according to the tentative EUCAST breakpoints, nine isolates showed MICs outside the WT distribution for erythromycin (see Table 1 ). So far, we have not searched for mutations in genes encoding 23S rRNA (rrl) and L4 (rplD) and L22 (rplV) ribosomal proteins that result in decreased susceptibility to macrolides. 7 In particular, the MIC 90 values ranged from 0.5 to 1.0 mg/L for fluoroquinolones (levofloxacin, moxifloxacin, ciprofloxacin). The 8 It was found that rifampicin is the most active drug against isolates with an MIC 90 of 0.032 mg/L under in vitro conditions. In contrast, doxycycline was found to be the least active drug, with an MIC 90 of 2.0 mg/L.
In summary, the in vitro activity of the tested antibiotics against the German clinical isolates was in agreement with results from other studies. [8] [9] [10] The introduction of routine susceptibility testing seems necessary for better understanding of the development of antibiotic resistance in vivo within the L. pneumophila population. Sir, The spread of carbapenemase-producing Klebsiella pneumoniae is a major public health concern since such isolates are basically resistant to most available antibiotics, including b-lactams, fluoroquinolones and aminoglycosides. 1 Infections due to carbapenemase-producing K. pneumoniae are therefore commonly treated with a regimen containing colistin. 1 However, acquired
